Does clozapine work by blocking spikes and sparing bursts?

Medical Hypotheses

Volumn 65, Issue 1, 2005, Pages 68-78

  Olson, Timothy P ^a  

^a West Central Mental Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ARTICLE; DISSOCIATION CONSTANT; DRUG EFFICACY; DRUG POTENCY; FEASIBILITY STUDY; MATHEMATICAL MODEL; PRIORITY JOURNAL; SIMULATION; SPIKE; SYNAPSE;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; COMPUTER SIMULATION; MATHEMATICS; MODELS, BIOLOGICAL; NEURONS; RECEPTORS, DOPAMINE D2; SEROTONIN ANTAGONISTS;

EID: 18944372867     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.01.035     Document Type: Article

References (99)

1. J.M. Van Rossum The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs Arch Int Pharmacodyn Ther 160 1966 492 494
2. I. Creese, D.R. Burt, and S.H. Snyder Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 192 1976 481 483
3. P. Seeman, T. Lee, M. Chau-Wong, and K. Wong Antipsychotic drug doses and neuroleptic/dopamine receptors Nature 261 1976 717 719
4. M. Kurz, M. Hummer, H. Oberbauer, and W.W. Fleischhacker Extrapyramidal side effects of clozapine and haloperidol Psychopharmacology (Berl) 118 1995 52 56
5. J. Geddes, N. Freemantle, P. Harrison, and P. Bebbington Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis BMJ 321 2000 1371 1376
6. S. Leucht, K. Wahlbeck, J. Hamann, and W. Kissling New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis Lancet 361 2003 1581 1589
7. J.M. Davis, N. Chen, and I.D. Glick A meta-analysis of the efficacy of second-generation antipsychotics Arch Gen Psychiatry 60 2003 553 564
8. H.S. Lee, C.H. Kim, D.H. Song, N.K. Choi, and K.J. Yoo Clozapine does not elevate serum prolactin levels in healthy men Biol Psychiatry 38 1995 762 764
9. J. Volavka, P. Czobor, and T.B. Cooper Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol J Clin Psychiatry 65 2004 57 61
10. K. Wahlbeck, M. Cheine, A. Essali, and C. Adams Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials Am J Psychiatry 156 1999 990 999
11. J. Kane, G. Honigfeld, J. Singer, and H. Meltzer Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine Arch Gen Psychiatry 45 1988 789 796
12. R. Rosenheck, J. Cramer, and W. Xu A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia: Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia N Engl J Med 337 1997 809 815
13. A.L. Nordstrom, L. Farde, S. Nyberg, P. Karlsson, C. Halldin, and G. Sedvall D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients Am J Psychiatry 152 1995 1444 1449
14. S. Kapur, R.B. Zipursky, and G. Remington Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia Am J Psychiatry 156 1999 286 293
15. J. Gerlach, and L. Peacock New antipsychotics: the present status Int Clin Psychopharmacol 10 Suppl. 3 1995 39 48
16. W.W. Shen A history of antipsychotic drug development Compr Psychiatry 40 1999 407 414
17. R. Tandon Cholinergic aspects of schizophrenia Br J Psychiatry 37 Suppl. 1999 7 11
18. R.J. Miller, and C.R. Hiley Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism Nature 248 1974 596 597
19. S. Snyder, D. Greenberg, and H.I. Yamamura Antischizophrenic drugs and brain cholinergic receptors: affinity for muscarinic sites predicts extrapyramidal effects Arch Gen Psychiatry 31 1974 58 61
20. R. Miller, J.R. Wickens, and R.J. Beninger Dopamine D-1 and D-2 receptors in relation to reward and performance: a case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs Prog Neurobiol 34 1990 143 183
21. P. Seeman Therapeutic receptor-blocking concentrations of neuroleptics Int Clin Psychopharmacol 10 Suppl. 3 1995 5 13
22. P. Karlsson, L. Smith, L. Farde, C. Harnryd, G. Sedvall, and F.A. Wiesel Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients Psychopharmacology (Berl) 121 1995 309 316
23. M.S. Kramer, B. Last, A. Getson, and S.A. Reines The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia: D4 Dopamine Antagonist Group Arch Gen Psychiatry 54 1997 567 572
24. S. Kapur A new framework for investigating antipsychotic action in humans: lessons from PET imaging Mol Psychiatry 3 1998 135 140
25. H.Y. Meltzer, S. Matsubara, and J.C. Lee Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values J Pharmacol Exp Ther 251 1989 238 246
26. A. Schotte, P.F. Janssen, and W. Gommeren Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding Psychopharmacology (Berl) 124 1996 57 73
27. J.A. Lieberman, R.B. Mailman, and G. Duncan Serotonergic basis of antipsychotic drug effects in schizophrenia Biol Psychiatry 44 1998 1099 1117
28. S. Kapur 5-HT2 antagonism and EPS benefits: is there a causal connection Psychopharmacology (Berl) 124 1996 35 39
29. B.J. Kinon, and J.A. Lieberman Mechanisms of action of atypical antipsychotic drugs: a critical analysis Psychopharmacology (Berl) 124 1996 2 34
30. S. Kapur, R. Zipursky, C. Jones, C.S. Shammi, G. Remington, and P. Seeman A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy Arch Gen Psychiatry 57 2000 553 559
31. M.J. Travis, G.F. Busatto, and L.S. Pilowsky 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine: a SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150 Br J Psychiatry 173 1998 236 241
32. G. Chouinard, B. Jones, and G. Remington A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients J Clin Psychopharmacol 13 1993 25 40
33. S.R. Marder, and R.C. Meibach Risperidone in the treatment of schizophrenia Am J Psychiatry 151 1994 825 835
34. P.I. Rosebush, and M.F. Mazurek Neurological side effects of risperidone Essent Psychopharmacol 3 1999 43 64
35. S. Kapur, G. Remington, R.B. Zipursky, A.A. Wilson, and S. Houle The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study Life Sci 57 1995 103 107
36. J. Lavalaye, D.H. Linszen, J. Booij, L. Reneman, B.P. Gersons, and E.A. Van Royen Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia Psychiatry Res 92 1999 33 44
37. S.R. David, C.C. Taylor, B.J. Kinon, and A. Breier The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia Clin Ther 22 2000 1085 1096
38. C.A. Stockmeier, J.J. DiCarlo, Y. Zhang, P. Thompson, and H.Y. Meltzer Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors J Pharmacol Exp Ther 266 1993 1374 1384
39. M. Hamner The effects of atypical antipsychotics on serum prolactin levels Ann Clin Psychiatry 14 2002 163 173
40. S.M. Stahl Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? J Clin Psychiatry 60 1999 425 426
41. R.E. Clark, S.J. Bartels, T.A. Mellman, and W.J. Peacock Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy Schizophr Bull 28 2002 75 84
42. R.E. McCue, R. Waheed, and L. Urcuyo Polypharmacy in patients with schizophrenia J Clin Psychiatry 64 2003 984 989
43. A. Fink-Jensen, T.S. Ludvigsen, and N. Korsgaard The effect of clozapine on Fos protein immunoreactivity in the rat forebrain is not mimicked by the addition of alpha 1-adrenergic or 5HT2 receptor blockade to haloperidol Neurosci Lett 194 1995 77 80
44. S. Kapur, and R.B. Zipursky Do loxapine plus cyproheptadine make an atypical antipsychotic? PET analysis of their dopamine D2 and serotonin2 receptor occupancy [letter] Arch Gen Psychiatry 55 1998 666 668
45. S. Kapur, and P. Seeman Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis Am J Psychiatry 158 2001 360 369
46. S.M. Stahl Hit-and-run actions at dopamine receptors, part 1: mechanism of action of atypical antipsychotics J Clin Psychiatry 62 2001 670 671
47. A.L. Nordstrom, L. Farde, and F.A. Wiesel Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients Biol Psychiatry 33 1993 227 235
48. S. Kapur, R. Zipursky, C. Jones, G. Remington, and S. Houle Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia Am J Psychiatry 157 2000 514 520
49. S. Tauscher-Wisniewski, S. Kapur, and J. Tauscher Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade J Clin Psychiatry 63 2002 992 997
50. O. Gefvert, M. Bergstrom, B. Langstrom, T. Lundberg, L. Lindstrom, and R. Yates Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia Psychopharmacology (Berl) 135 1998 119 126
51. L. Farde, A.L. Nordstrom, F.A. Wiesel, S. Pauli, C. Halldin, and G. Sedvall Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects Arch Gen Psychiatry 49 1992 538 544
52. S. Nyberg, A.L. Nordstrom, C. Halldin, and L. Farde Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man Int Clin Psychopharmacol 10 Suppl. 3 1995 81 85
53. B.A. Horger, and R.H. Roth The role of mesoprefrontal dopamine neurons in stress Crit Rev Neurobiol 10 1996 395 418
54. E.L. Gardner, and C.R. Ashby Heterogeneity of the mesotelencephalic dopamine fibers: physiology and pharmacology Neurosci Biobehav Rev 24 2000 115 118
55. L.A. Chiodo Dopamine-containing neurons in the mammalian central nervous system: electrophysiology and pharmacology Neurosci Biobehav Rev 12 1988 49 91
56. W. Softky, and C. Koch Single-cell models M.A. Arbib The handbook of brain theory and neural networks 1995 MIT Press Cambridge, MA 879 884
57. F.G. Gonon Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry Neuroscience 24 1988 19 28
58. A.J. Bean, and R.H. Roth Extracellular dopamine and neurotensin in rat prefrontal cortex in vivo: effects of median forebrain bundle stimulation frequency, stimulation pattern, and dopamine autoreceptors J Neurosci 11 1991 2694 2702
59. K.T. Kawagoe, P.A. Garris, D.J. Wiedemann, and R.M. Wightman Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum Neuroscience 51 1992 55 64
60. S.B. Ross Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism J Neurochem 56 1991 22 29
61. M. Laruelle, C.D. D'Souza, and R.M. Baldwin Imaging D2 receptor occupancy by endogenous dopamine in humans Neuropsychopharmacology 17 1997 162 174
62. A. Abi-Dargham, J. Rodenhiser, and D. Printz Increased baseline occupancy of D2 receptors by dopamine in schizophrenia Proc Natl Acad Sci USA 97 2000 8104 8109
63. P. Seeman, and T. Tallerico Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors Mol Psychiatry 3 1998 123 134
64. D.H. Jenkinson Classical approaches to the study of drug-receptor interactions J.C. Foreman T. Johansen Textbook of receptor pharmacology 1996 CRC Press Boca Raton 18
65. T. Kenakin Pharmacologic analysis of drug-receptor interaction 3rd ed. 1997 Lippincott-Raven Philadelphia, PA p. 446
66. V.A. Boundy, M.A. Pacheco, W. Guan, and P.B. Molinoff Agonists and antagonists differentially regulate the high affinity state of the D2L receptor in human embryonic kidney 293 cells Mol Pharmacol 48 1995 956 964
67. P. Seeman, T. Tallerico, F. Ko, C. Tenn, and S. Kapur Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges Synapse 46 2002 235 239
68. L.A. Taylor, and I. Creese Regulation of neurotransmitter receptors by antipsychotic drugs M.S. Lidow Neurotransmitter receptors in actions of antipsychotic medications 2000 CRC Press Boca Raton 177 198
69. G. Remington, and S. Kapur D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET J Clin Psychiatry 60 Suppl. 10 1999 15 19
70. S. Leucht, G. Pitschel-Walz, D. Abraham, and W. Kissling Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Schizophr Res 35 1999 51 68
71. Parkinson Study Group Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease N Engl J Med 340 1999 757 763
72. J.H. Friedman, and S.A. Factor Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease Mov Disord 15 2000 201 211
73. D.E. Casey Tardive dyskinesia: pathophysiology and animal models J Clin Psychiatry 61 Suppl. 4 2000 5 9
74. J.M. Kane, M.G. Woerner, S. Pollack, A.Z. Safferman, and J.A. Lieberman Does clozapine cause tardive dyskinesia J Clin Psychiatry 54 1993 327 330
75. T.R. Barnes, and M.A. McPhillips Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia Int Clin Psychopharmacol 13 Suppl. 3 1998 49 57
76. W.M. Glazer Review of incidence studies of tardive dyskinesia associated with typical antipsychotics J Clin Psychiatry 61 Suppl. 4 2000 15 20
77. R.G. Petty Prolactin and antipsychotic medications: mechanism of action Schizophr Res 35 Suppl. 1999 67 73
78. R.A. Dickson, and W.M. Glazer Neuroleptic-induced hyperprolactinemia Schizophr Res 35 Suppl. 1999 75 86
79. S. Smith, M.J. Wheeler, R. Murray, and V. O'Keane The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis J Clin Psychopharmacol 22 2002 109 114
80. C.N. Soares, O.P. Almeida, H. Joffe, and L.S. Cohen Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial Arch Gen Psychiatry 58 2001 529 534
81. S.M. Stahl Sex and psychopharmacology: is natural estrogen a psychotropic drug in women Arch Gen Psychiatry 58 2001 537 538
82. J. Montgomery, E. Winterbottom, and M. Jessani Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment J Clin Psychiatry 65 2004 1491 1498
83. H.G. El-Sayeh, and C. Morganti Aripiprazole for schizophrenia Cochrane Database Syst Rev CD004578 2004
84. C.J. Bench, A.A. Lammertsma, and R.J. Dolan Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride Psychopharmacology (Berl) 112 1993 308 314
85. F. Yokoi, G. Grunder, and K. Biziere Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride Neuropsychopharmacology 27 2002 248 259
86. J.L. Martinot, M.L. Paillere-Martinot, M.F. Poirier, M.H. Dao-Castellana, C. Loc'h, and B. Maziere In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia Psychopharmacology (Berl) 124 1996 154 158
87. P. Seeman, and T. Tallerico Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine Am J Psychiatry 156 1999 876 884
88. O. Gefvert, T. Lundberg, and I.M. Wieselgren D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study Eur Neuropsychopharmacol 11 2001 105 110
89. K.L. Davis, R.S. Kahn, G. Ko, and M. Davidson Dopamine in schizophrenia: a review and reconceptualization Am J Psychiatry 148 1991 1474 1486
90. E. Richelson, and A. Nelson Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro Eur J Pharmacol 103 1984 197 204
91. L.S. Pilowsky, R.S. Mulligan, P.D. Acton, P.J. Ell, D.C. Costa, and R.W. Kerwin Limbic selectivity of clozapine Lancet 350 1997 490 491
92. M. Talvik, A.L. Nordstrom, S. Nyberg, H. Olsson, C. Halldin, and L. Farde No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457 Am J Psychiatry 158 2001 926 930
93. H. Olsson, and L. Farde Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy: a simulation study based on experimental data Neuroimage 14 2001 936 945
94. J. Grenhoff, L. Ugedo, and T.H. Svensson Firing patterns of midbrain dopamine neurons: differences between A9 and A10 cells Acta Physiol Scand 134 1988 127 132
95. S.W. Woods Chlorpromazine equivalent doses for the newer atypical antipsychotics J Clin Psychiatry 64 2003 663 667
96. M.J. Dewan, and M. Koss The clinical impact of reported variance in potency of antipsychotic agents Acta Psychiatr Scand 91 1995 229 232
97. R. Miller Dose-response relationships for the antipsychotic effects and Parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications Prog Neuropsychopharmacol Biol Psychiatry 21 1997 1059 1094
98. C.R. Young, M.B. Bowers, and C.M. Mazure Management of the adverse effects of clozapine Schizophr Bull 24 1998 381 390
99. D.C. Henderson Clozapine: diabetes mellitus, weight gain, and lipid abnormalities J Clin Psychiatry 62 Suppl. 23 2001 39 44